Atai Life Sciences spotlights early depression data for psychedelic ahead of big readout
27 Mar 2024
Phase 2Clinical Result
Less than two months after betting $50 million on Beckley Psytech’s psychedelic drugs, atai Life Sciences has shared initial Phase 2a results for one candidate that it says support its use in treatment-resistant depression.
In an open-label study involving 12 patients — 11 of whom were included for analysis — a single dose of Beckley Psytech’s BPL-003 had an antidepressant response on day 2, as measured by the Montgomery–Åsberg Depression Rating Scale. At week 4, 55% of patients were in remission, and 45% were still in remission at week 12, according to atai.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.